Singapore HSA
Material regulatory developments from Health Sciences Authority are tracked daily by Cresthaven Analytics. Over the last 90 days, 20 material briefs relevant to professionals operating in the healthcare & life sciences sector have been published below. Each brief is sourced directly from the primary regulatory feed, summarized for institutional readers, and scored for materiality.
Recent material activity
-
HSA warns against three adulterated health products after serious adverse events including a paediatric case
The Health Sciences Authority issued a public warning on 23 July 2026 against three products marketed as supplements or herbal remedies. Laboratory analysis confirmed each product contained undeclared potent or banned me…
Read a full sample brief → -
HSA initiates retail-level recall of seven BD ChloraPrep 1 mL Applicator batches over sterility breach risk
Singapore's Health Sciences Authority issued a retail-level recall on July 17, 2026 covering seven batches of BD ChloraPrep 1 mL Applicator (Clear) due to potential packaging sterility breaches. The action requires remov…
Read a full sample brief → -
HSA discontinues mandatory HCP education, certification, and related risk-management requirements for tolvaptan (Jinarc) in Singapore
Singapore's Health Sciences Authority announced on July 15, 2026 the discontinuation of mandatory healthcare professional education, certification, and associated requirements under the Risk Management Plan for Jinarc (t…
Read a full sample brief → -
HSA orders retail-level recall of all in-date Decondine Syrup batches over out-of-specification quality failures
Singapore's Health Sciences Authority issued a retail-level recall on July 14, 2026 covering all batches of Decondine Syrup within expiry. The recall was triggered by out-of-specification results for triprolidine assay, …
Read a full sample brief → -
HSA orders retail-level recall of Remethan 100 R Tablet 100 mg over out-of-specification stability results
Singapore's Health Sciences Authority issued a retail-level recall of one batch of Remethan 100 R Tablet 100 mg on July 10, 2026, triggered by out-of-specification results from stability batch testing.
Read a full sample brief → -
HSA charges individual for importing etomidate vaporiser pods under Singapore's controlled substances framework
Singapore's Health Sciences Authority charged a 24-year-old male on July 9, 2026 for allegedly importing etomidate vaporiser pods in contravention of the controlled substances framework. This appears to be the first enfo…
Read a full sample brief → -
HSA extends e-labelling framework to Pharmacy and General Sale List medicines effective 30 June 2026
Singapore's Health Sciences Authority extended its e-labelling framework to Pharmacy (P) and General Sale List (GSL) medicines on 30 June 2026. The update expands a labelling pathway previously limited to prescription pr…
Read a full sample brief → -
HSA opens public consultation on a proposed regulatory framework for complementary health products under Singapore's Health Products Act
Singapore's Health Sciences Authority launched a stakeholder consultation on July 1, 2026 on proposed regulations governing complementary health products under the Health Products Act. The consultation signals HSA's inte…
Read a full sample brief → -
HSA opens public consultation on a proposed regulatory framework for complementary health products under Singapore's Health Products Act
Singapore's Health Sciences Authority launched a stakeholder consultation on July 1, 2026 proposing a dedicated regulatory framework for complementary health products under the Health Products Act. The proposal would est…
Read a full sample brief → -
HSA extends e-labelling framework to Pharmacy and General Sale List medicines effective 30 June 2026
Singapore's Health Sciences Authority (HSA) extended e-labelling to Pharmacy (P) and General Sale List (GSL) medicines on 30 June 2026. This expands a framework previously limited to prescription products to cover two ad…
Read a full sample brief → -
HSA orders retail-level recall of four BD ChloraPrep 1 mL Applicator batches over sterility breach risk
Singapore's Health Sciences Authority issued a retail-level recall on June 15, 2026 covering four batches of BD ChloraPrep 1 mL Applicator, Clear. The recall addresses a potential sterility breach in the product packagin…
Read a full sample brief → -
HSA identifies mercury and prohibited ingredients in whitening and anti-ageing cosmetic products sold in Singapore
Singapore's Health Sciences Authority (HSA) issued a public safety alert on May 29, 2026 identifying whitening and anti-ageing products containing mercury and other prohibited ingredients. The alert directs consumers and…
Read a full sample brief → -
HSA Singapore warns against skin products from unverified sources citing serious adverse health effects
On May 29, 2026, the Health Sciences Authority of Singapore issued a public advisory warning against the use of skin products sourced from dubious or unknown suppliers. The advisory signals continued HSA enforcement atte…
Read a full sample brief → -
HSA issues updated safety guidance on allopurinol prescribing and patient screening requirements
Singapore's Health Sciences Authority published a safety communication on May 28, 2026 addressing the safe use of allopurinol, a xanthine oxidase inhibitor indicated for gout and hyperuricemia. The release addresses pres…
Read a full sample brief → -
HSA issues public warning against unlicensed 'magic water' facial solution linked to chemical burns
Singapore's Health Sciences Authority issued a public warning on May 28, 2026 identifying an unlicensed facial solution marketed as 'magic water' as the cause of reported skin peeling and chemical burns. HSA has not appr…
Read a full sample brief → -
HSA files trafficking charge against individual for alleged distribution of etomidate vaporiser pods in Singapore
Singapore's Health Sciences Authority charged a 25-year-old male on May 27, 2026 for alleged trafficking of etomidate vaporiser pods under the Medicines Act (Cap. 176). The action signals active HSA enforcement against u…
Read a full sample brief → -
HSA Singapore issues public safety alert linking undeclared corticosteroid in herbal product to iatrogenic Cushing's Syndrome
The Health Sciences Authority of Singapore issued a safety alert on May 19, 2026 identifying an undeclared potent corticosteroid in a herbal product associated with a confirmed case of Cushing's Syndrome in an elderly pa…
Read a full sample brief → -
HSA Singapore identifies undeclared potent corticosteroid in herbal product linked to iatrogenic Cushing's Syndrome
The Health Sciences Authority of Singapore issued a press release on May 20, 2026, reporting that an elderly woman developed Cushing's Syndrome after consuming an herbal product found to contain an undeclared potent cort…
Read a full sample brief → -
HSA issues Dear Healthcare Professional Letter for Evrysdi risdiplam over foreign particle contamination risk
Singapore's Health Sciences Authority issued a Dear Healthcare Professional Letter on May 15, 2026 concerning Evrysdi (risdiplam) 0.75 mg/mL Powder for Oral Solution. The letter addresses the potential presence of insolu…
Read a full sample brief → -
HSA orders retail-level recall of 18 AA Pharma Hydroxyzine Capsule batches for incorrect shelf life labelling
The Health Sciences Authority of Singapore issued a retail-level recall on May 12, 2026 covering five batches of AA Pharma Hydroxyzine Capsule 10mg and thirteen batches of AA Pharma Hydroxyzine Capsule 25mg. The recall i…
Read a full sample brief →
Get every Singapore HSA brief delivered the day it lands
From $149/month
Cresthaven Analytics monitors Health Sciences Authority continuously, applying institutional materiality scoring to every release. Subscribers receive structured briefs via email, portal, and (Executive tier and above) real-time alerts.
View all tiers →